Literature DB >> 32238636

[Synthetic Studies on Developments for Bioactive New Leads of Oligovalent Symmetrical Molecules].

Kunihiro Sumoto1.   

Abstract

Interactions between carbohydrate-containing glycoproteins, proteoglycans, and glycolipids on the cell surface are important biological stages for the processes of bacterial or viral infection and tumor metastasis. Moreover, supramolecular interaction by macromolecules with two-fold (C2) or three-fold (C3) geometry is one of the common interactions in many important biological responses. To develop new multivalent symmetrical bioactive compounds or leads, we designed and synthesized several new molecules with these geometries and evaluated their bioactivities in an attempt to find new types of bioactive leads that may interfere with the sugar recognition process. We evaluated bioactivities including antibacterial, antiviral, and anticancer activities of targeted molecules in vitro using biological assay systems. Among the synthesized target derivatives examined, some bivalent symmetrical derivatives showed high levels of bioactivities. In this review, the author describes the results of synthesis of oligovalent symmetrical target compounds and some interesting guiding results of evaluation of their biological activities and structure-activity relationships.

Entities:  

Keywords:  biological activity; hydantoin; oligovalent symmetrical molecule; phenylboronic acid; sugar recognition; triazane

Year:  2020        PMID: 32238636     DOI: 10.1248/yakushi.19-00222

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  1 in total

1.  Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.

Authors:  Alexis Paquin; Yassine Oufqir; Irina F Sevrioukova; Carlos Reyes-Moreno; Gervais Bérubé
Journal:  Eur J Med Chem       Date:  2021-04-24       Impact factor: 7.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.